Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Piotr Smolewski & Dominika Rydygier. (2019) Ixazomib: an investigational drug for the treatment of lymphoproliferative
disorders. Expert Opinion on Investigational Drugs 28:5, pages 421-433.
Read now
Read now
Bruce Bostrom. (2016) Bortezomib for the treatment of acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 4:7, pages 775-780.
Read now
Read now
Eileen Mary Boyle & Franck Morschhauser. (2015) Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Safety 14:4, pages 601-607.
Read now
Read now
Articles from other publishers (27)
Feyzanur Caldiran, Caglar Berkel, Esra Yilmaz, Burak Kucuk, Aslihan Hatun Cacan, Senol Citli, Emel Canpolat & Ercan Cacan. (2023) Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. Biochemical and Biophysical Research Communications 675, pages 33-40.
Crossref
Crossref
Kainat Ahmed & Sudhakar Jha. (2023) Oncoviruses: How do they hijack their host and current treatment regimes. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:5, pages 188960.
Crossref
Crossref
Justyna Derebas, Kinga Panuciak, Mikołaj Margas, Joanna Zawitkowska & Monika Lejman. (2022) The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers 14:6, pages 1569.
Crossref
Crossref
Min Seung Lee, So Hyun Lim, Ah-Ran Yu, Chi Yeon Hwang, Insug Kang & Eui-Ju Yeo. (2021) Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells. Biology 10:2, pages 153.
Crossref
Crossref
Huanjie Yang, Xin Chen, Kai Li, Hassan Cheaito, Qianqian Yang, Guojun Wu, Jinbao Liu & Q. Ping Dou. (2021) Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Seminars in Cancer Biology 68, pages 105-122.
Crossref
Crossref
Feifei Sun, Xiaosheng Fang & Xin Wang. (2020) Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. Anti-Cancer Agents in Medicinal Chemistry 19:17, pages 2047-2059.
Crossref
Crossref
Aimen K. Aljoundi, Clement Agoni, Fisayo A. Olotu & Mahmoud E.S. Soliman. (2019) Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. Anti-Cancer Agents in Medicinal Chemistry 19:11, pages 1325-1339.
Crossref
Crossref
Immacolata Cozzolino, Valentina Giudice, Chiara Mignogna, Carmine Selleri, Alessandro Caputo & Pio Zeppa. (2019) Lymph node fine‐needle cytology in the era of personalised medicine. Is there a role?. Cytopathology 30:4, pages 348-362.
Crossref
Crossref
Carlyn Rose C. Tan, Saif Abdul-Majeed, Brittany Cael & Stefan K. Barta. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clinical Pharmacokinetics 58:2, pages 157-168.
Crossref
Crossref
Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun & Steven Grant. (2018) Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer 18:1.
Crossref
Crossref
Wei Liu, Juan Chen, Archito T. Tamayo, Changgeng Ruan, Li Li, Shouhao Zhou, Chan Shen, Ken H. Young, Jason Westin, Richard E. Davis, Shimin Hu, Leonard J. Medeiros, Richard J. Ford & Lan V. Pham. (2017) Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9:1, pages 346-360.
Crossref
Crossref
Natalie A Duggett & Sarah J L Flatters. (2017) Characterization of a rat model of bortezomib-induced painful neuropathy. British Journal of Pharmacology 174:24, pages 4812-4825.
Crossref
Crossref
N.M. Reddy & C. Thieblemont. (2017) Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Annals of Oncology 28:11, pages 2680-2690.
Crossref
Crossref
Michiel van den Brand, Blanca Scheijen, Corine J. Hess, J. Han JM van Krieken & Patricia J.T.A. Groenen. (2017) Pathways towards indolent B-cell lymphoma — Etiology and therapeutic strategies. Blood Reviews 31:6, pages 426-435.
Crossref
Crossref
Jacob M Core, Ali A Alsaad, Liuyan Jiang & Neal M Patel. (2017) Nodular pulmonary amyloidosis: a complex disease with malignancy association. BMJ Case Reports, pages bcr-2017-220428.
Crossref
Crossref
Irfan Ahmed Bhatti, Behnaz Ahangarian Abhari & Simone Fulda. (2017) Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. Cancer Letters 405, pages 63-72.
Crossref
Crossref
Wen-Fang Wang, Li Yan, Zhao Liu, Lan-Xuan Liu, Jian Lin, Zhi-Yin Liu, Xiong-Ping Chen, Wu Zhang, Zi-Zhen Xu, Ting Shi, Jun-Min Li, Yi-Lei Zhao, Guoyu Meng, Yi Xia, Jian-Yong Li & Jiang Zhu. (2017) HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells. Nature Communications 8:1.
Crossref
Crossref
Ting Yuan, Feng Zhang, Qing-min Yao, Yan-xia Liu, Xiao-juan Zhu & Xin Wang. (2017) Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis. PLOS ONE 12:5, pages e0177950.
Crossref
Crossref
Helen Ma & Maher Abdul-Hay. (2016) T-cell lymphomas, a challenging disease: types, treatments, and future. International Journal of Clinical Oncology 22:1, pages 18-51.
Crossref
Crossref
M N Cruickshank, J Ford, L C Cheung, J Heng, S Singh, J Wells, T W Failes, G M Arndt, N Smithers, R K Prinjha, D Anderson, K W Carter, A M Gout, T Lassmann, J O'Reilly, C H Cole, R S Kotecha & U R Kees. (2016) Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia 31:1, pages 40-50.
Crossref
Crossref
Daolin Wei, Yin Tong, Haitao Bai, Qi Cai, Yanrong Gao & Chun Wang. (2016) A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma. Oncotarget 7:43, pages 70168-70174.
Crossref
Crossref
Bryan Hambley, Paolo F. Caimi & Basem M. William. (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology 7:4, pages 196-208.
Crossref
Crossref
Sergei Vatolin, James G. Phillips, Babal K. Jha, Shravya Govindgari, Jennifer Hu, Dale Grabowski, Yvonne Parker, Daniel J. Lindner, Fei Zhong, Clark W. Distelhorst, Mitchell R. Smith, Claudiu Cotta, Yan Xu, Sujatha Chilakala, Rebecca R. Kuang, Samantha Tall & Frederic J. Reu. (2016) Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Research 76:11, pages 3340-3350.
Crossref
Crossref
Fabio Penna, Andrea Bonetto, Zaira Aversa, Valerio Giacomo Minero, Filippo Rossi Fanelli, Paola Costelli & Maurizio Muscaritoli. (2016) Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. Journal of Cachexia, Sarcopenia and Muscle 7:3, pages 345-354.
Crossref
Crossref
C Liu, L Zheng, H Wang, X Ran, H Liu & X Sun. (2015) The RCAN1 inhibits NF-κB and suppresses lymphoma growth in mice. Cell Death & Disease 6:10, pages e1929-e1929.
Crossref
Crossref
Johannes Kraus, Marianne Kraus, Nora Liu, Lenka Besse, Jürgen Bader, Paul P. Geurink, Gerjan de Bruin, Alexei F. Kisselev, Herman Overkleeft & Christoph Driessen. (2015) The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemotherapy and Pharmacology 76:2, pages 383-396.
Crossref
Crossref
Hou Yun, Hui lai Zhang & Hua-qing Wang. (2014) Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. Medical Oncology 32:1.
Crossref
Crossref